A replay of the corporate presentation will be available on the Events section of the company’s Investor Relations website.
an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback